WAYNE, Pa., Feb. 7, 2013 /PRNewswire/ -- Molecular Detection Inc. (MDI), which develops and markets Detect-Ready® assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced major patent advances in the US and Europe. A second core US patent has issued covering key aspects of MDI's technology platform that assesses multiple gene targets to accurately distinguish between samples containing antibiotic-sensitive and antibiotic-resistant bacteria. Additionally, the company has received a notice of acceptance from the European Patent Office for an analogous patent application in Europe.
The US Patent and Trademark Office issued US Patent No. 8362228, "Methods, Compositions and Kits for Detection and Analysis of Antibiotic-Resistant Bacteria," on January 29, 2013. This is the second US patent in this area awarded to MDI, following on and expanding US Patent No.8,017,337. The accepted European application (European Patent Application No. 08799821.7) is expected to issue in the coming months.
MDI's Detect-Ready MRSA assay has the unique capability to distinguish between MRSA (methicillin-resistant Staphylococcus aureus), MSSA (methicillin-sensitive S. aureus) and mixed populations of bacteria by amplifying and evaluating multiple gene targets. MDI has also demonstrated the ability of the Detect-Ready technology to distinguish between antibiotic-sensitive and antibiotic-resistant strains in other bacterial pathogens. The company is developing a number of assays for these pathogens, such as a test for the early detection of resistant infections associated with sepsis.
"These patent advances in the US and Europe further confirm the advantages of MDI's approach," said Todd Wallach , CEO and chairman of MDI. "They reinforce the growing body of da
|SOURCE Molecular Detection Inc.|
Copyright©2012 PR Newswire.
All rights reserved